Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Development deals
Biotech
Lilly inks $345M antibody pact with XtalPi subsidiary
The Big Pharma will be able to nominate an undisclosed number of target pairs for bispecific development.
Darren Incorvaia
Nov 5, 2025 7:00am
Boehringer's deal frenzy continues with $570M autoimmune pact
Nov 4, 2025 8:00am
Regeneron pledges $1B+ for ModeX multispecific antibodies
Oct 29, 2025 11:04am
Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal
Oct 6, 2025 7:00am
Gilead's Kite erodes $2.3B Shoreline cell therapy deal
Sep 3, 2025 3:18pm
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
